Morphic Holding Future Growth

Future criteria checks 2/6

Morphic HoldingDie Gewinne des Unternehmens werden voraussichtlich um 14.7% pro Jahr sinken, während die jährlichen Einnahmen um 8.3% pro Jahr steigen werden. Der Gewinn pro Aktie wird voraussichtlich decline um 9% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -41.3% betragen.

Key information

-7.4%

Earnings growth rate

-0.8%

EPS growth rate

Biotechs earnings growth	20.9%
Revenue growth rate	71.4%
Future return on equity	-121.5%
Analyst coverage	Good
Last updated	13 Mar 2024

Recent future growth updates

Recent updates

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Mar 09

Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

Feb 24

How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Jan 20

Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Dec 16

Earnings and Revenue Growth Forecasts

NasdaqGM:MORF - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1	-243	-202	-206	7
12/31/2025	1	-225	-190	-194	8
12/31/2024	0	-196	-158	-160	10
12/31/2023	1	-152	-114	-112	N/A
9/30/2023	7	-136	-110	-109	N/A
6/30/2023	9	-130	-106	-104	N/A
3/31/2023	69	-64	-105	-104	N/A
12/31/2022	71	-59	-101	-101	N/A
9/30/2022	74	-56	-97	-96	N/A
6/30/2022	75	-51	-97	-96	N/A
3/31/2022	19	-106	-92	-91	N/A
12/31/2021	20	-96	-84	-83	N/A
9/30/2021	16	-92	-78	-77	N/A
6/30/2021	39	-61	-49	-49	N/A
3/31/2021	43	-50	-48	-47	N/A
12/31/2020	45	-45	-47	-46	N/A
9/30/2020	39	-47	-47	-46	N/A
6/30/2020	19	-61	-65	-63	N/A
3/31/2020	17	-55	-63	-61	N/A
12/31/2019	17	-43	-44	-42	N/A
9/30/2019	21	-29	63	65	N/A
6/30/2019	15	-27	72	73	N/A
3/31/2019	9	-24	81	82	N/A
12/31/2018	3	-24	76	76	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MORF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MORFDie Einnahmen des Unternehmens (8.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: MORFDie Einnahmen des Unternehmens (65% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: MORF wird voraussichtlich in 3 Jahren unrentabel sein.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Morphic Holding Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 88%, EPS upgraded

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Price target decreased by 13% to US$65.38

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

Recent updates

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock

Consensus EPS estimates fall to -US$2.73

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Insider notifies of intention to sell stock

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress